These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27802290)

  • 41. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).
    Yokota O; Terada S; Ishizu H; Tsuchiya K; Kitamura Y; Ikeda K; Uéda K; Kuroda S
    Acta Neuropathol; 2002 Oct; 104(4):333-41. PubMed ID: 12200618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
    Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
    Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.
    Irwin DJ; Lee VM; Trojanowski JQ
    Nat Rev Neurosci; 2013 Sep; 14(9):626-36. PubMed ID: 23900411
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
    J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The morbid anatomy of dementia in Parkinson's disease.
    Kalaitzakis ME; Pearce RK
    Acta Neuropathol; 2009 Nov; 118(5):587-98. PubMed ID: 19820956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
    Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of naturally occurring α-synuclein-antibodies on toxic α-synuclein-fragments.
    Rabenstein M; Besong Agbo D; Wolf E; Dams J; Nicolai M; Roeder A; Bacher M; Dodel RC; Noelker C
    Neurosci Lett; 2019 Jun; 704():181-188. PubMed ID: 30954607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
    Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L
    JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [11C]PIB binding in Parkinson's disease dementia.
    Maetzler W; Reimold M; Liepelt I; Solbach C; Leyhe T; Schweitzer K; Eschweiler GW; Mittelbronn M; Gaenslen A; Uebele M; Reischl G; Gasser T; Machulla HJ; Bares R; Berg D
    Neuroimage; 2008 Feb; 39(3):1027-33. PubMed ID: 18035558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Striatal beta-amyloid deposition in Parkinson disease with dementia.
    Kalaitzakis ME; Graeber MB; Gentleman SM; Pearce RK
    J Neuropathol Exp Neurol; 2008 Feb; 67(2):155-61. PubMed ID: 18219254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amyloid PET Imaging in Lewy body disorders.
    Donaghy P; Thomas AJ; O'Brien JT
    Am J Geriatr Psychiatry; 2015 Jan; 23(1):23-37. PubMed ID: 23831180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies.
    Nielsen HM; Hall S; Surova Y; Nägga K; Nilsson C; Londos E; Minthon L; Hansson O; Wennström M
    J Alzheimers Dis; 2014; 40(2):343-50. PubMed ID: 24448788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential Circulating Levels of Naturally Occurring Antibody to α-Synuclein in Parkinson's Disease Dementia, Alzheimer's Disease, and Vascular Dementia.
    Wang J; Zheng B; Yang S; Hu M; Wang JH
    Front Aging Neurosci; 2020; 12():571437. PubMed ID: 33088272
    [No Abstract]   [Full Text] [Related]  

  • 60. Naturally Occurring Antibodies to Tau Exists in Human Blood and Are Not Changed in Alzheimer's Disease.
    Yu ZY; Li WW; Yang HM; Mañucat-Tan NB; Wang J; Wang YR; Sun BL; Hu ZC; Zhang LL; Tan L; Deng J; Liu YH
    Neurotox Res; 2020 Apr; 37(4):1029-1035. PubMed ID: 32026360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.